$JAKK

Jakks Pacific (JAKK) Misses Q3 Earnings and Revenue Estimates

Jakks (JAKK) delivered earnings and revenue surprises of -30.77% and -18.99%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 30, 2025, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jakks Pacific (JAKK) Misses Q3 Earnings and Revenue Estimates — source image
Decision brief

The 30-second read

$JAKKBearishMed
01

Why it matters

The earnings miss has led to a decline in stock price, impacting investor sentiment and potentially affecting related stocks in the sector.

02

Market read

The news has immediate relevance for traders holding or considering positions in JAKK, with potential sector-wide implications.

03

What to watch

Potential for upcoming product launches or strategic initiatives that could mitigate negative sentiment in the medium term

Relevance 6/10Timing: short-term (next 1-2 weeks)

Background

Jakks Pacific reported Q3 earnings and revenue below analyst estimates, with significant negative surprises. The company operates in the toy and entertainment manufacturing sector, which is sensitive to consumer spending trends.

Company-level read

Ticker impact

$JAKKBearishHigh confidence
Context

Primary focus due to recent earnings miss

Expected impact

Potential short-term decline of 5-10% in stock price

Evidence & confidence

Large earnings and revenue misses typically lead to immediate stock price declines, especially when surprises are substantial. The negative sentiment is reinforced by the magnitude of the misses.

Market effects

Potential negative sentiment in toy and entertainment manufacturing sectors

Limited regional impact, primarily affecting US-based toy manufacturers

Low, as the company has limited global exposure

Counterpoint

The earnings miss may be a short-term anomaly; the company could rebound if underlying issues are temporary

Key entities

  • Jakks Pacific

    A manufacturer of toys and entertainment products.

Related articles

$JAKKMed

JAKKS Pacific (JAKK) Q2 2026 Earnings Call Transcript

JAKKS Pacific held its Q2 2026 earnings call, saying net sales rose 17% to $139.2M year over year and were $245.9M for the first half, up 6%. International shipping hit $53M for the first half. Gross margin was 32.3%. Operating loss was $142K and adjusted EBITDA was $5.4M. The company said it received essentially all IEPA tariff refunds by Q2 close.

LowAI 8/10

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne – Thailand Business News

Ascletis Pharma Inc.'s partner, Sagimet Biosciences, has dosed the first patient in a Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial aims to enroll 800 patients. Ascletis' prior Phase III trial in China showed ASC40 was more effective than FDA-approved treatments, with 18.6% treatment success vs. 9.4% for sarecycline and 6.7% for doxycycline.